Using FAERS Data as a Proxy to Determine Medical Costs for TNF alpha Inhibitors
For full access to this free poster, please complete the form on the right side of this page.
Presented at the Association of Managed Care Pharmacy (AMCP) conference in March 2017, this poster and abstract:
- Pairs FAERS data with specific claims data to determine downstream medical costs of adverse events associated with TNFa Inhibitors Humira (adalimumab), Enbrel (etanercept), Cimzia (certolizumab pegol), Remicade (infliximab), Simponi (golimumab), and Simponi Aria (golimumab).
- Uses Advera’s Evidex platform to validate a hypothesis that the reporting rate of pneumonia as an adverse event in FAERS would be similar to the incidence rate of pneumonia as an adverse event in the WEA Trust medical claims database
- Concludes that higher incidence of pneumonia caused by certain TNF alpha inhibitors would result in higher downstream medical costs
- WEA Trust claims data showed that Cimzia had a statistically significant adverse event incidence rate of 13.6% for pneumonia, whereas Simponi had an adverse event incidence of 40%, as compared to Humira and Enbrel which each had an adverse event incidence rate of 0.5%
- The downstream costs due to emergency room visits were on average $522 per dispense for Cimzia as compared to $256 for Humira and $190 for Enbrel
- These findings correlate with the downstream costs calculations from Advera which estimates Cimzia having the highest downstream costs ($86 per dispense) with Humira ($66) and Enbrel ($59) having lower downstream costs
Please note: This is an independent analysis conducted by Advera Health, based upon data and insight generated by the analytical tools of Evidex and other pertinent information gathered at the time of publication. This analysis is not sponsored or influenced by any third party. The inclusion of a particular company, drug, adverse event, class or indication in this report is determined wholly by our quantitative signaling and analytic systems along with our qualitative analysis work.